JOEL MORCILLA: Open Payments
NPI 1942832191 · BAYTOWN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$639 in 27 payments from 13 companies in 2025. Trend: 2023 $442 · 2024 $401 · 2025 $639
Food & beverage: $639
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 7 | $203 |
| Lilly USA, LLC | 3 | $71 |
| Sumitomo Pharma America, Inc. | 3 | $69 |
| AstraZeneca Pharmaceuticals LP | 3 | $54 |
| Exact Sciences Corporation | 2 | $53 |
| Astellas Pharma US Inc | 2 | $44 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $28 |
| E.R. Squibb & Sons, L.L.C. | 1 | $27 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
| Avvisto Therapeutics, LLC | 1 | $19 |
Products named: REPATHA, GEMTESA, OTEZLA, Cologuard Collection Kit, JARDIANCE, MOUNJARO, Veozah, FARXIGA.
Industry payments across TX — which companies pay providers there.
